This pharmaceutical company establishes a record date for the dividend!

This pharmaceutical company establishes a record date for the dividend!

Siddharth Mane
/ Categories: Trending, Mindshare

The company has delivered returns of 22 per cent over the past year and great returns of 110 per cent over the past 3 years.

Sun Pharma is the world's fourth largest specialty generics company, operating in Specialty, Generics, and Consumer Healthcare products. They are the largest pharmaceutical company in India and a leading generics company in the US and Global Emerging Markets. Sun Pharma's high-growth Global Specialty portfolio includes innovative products in dermatology, ophthalmology, and onco-dermatology, contributing over 16% of their sales.

With vertically integrated operations, they provide trusted, high-quality medicines to over 100 countries. Sun Pharma takes pride in its multicultural workforce from over 50 nations, and its manufacturing facilities span across six continents.

DSIJ offers a service 'Large Rhino' with recommendations for Large-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the service details pdf here

Sun Pharma has set the record date for the final dividend of Rs. 4.00 per equity share for FY2022-23 as Friday, July 28, 2023. This date will determine the eligible members who will receive the dividend. If approved at the 31st Annual General Meeting, the final dividend will be paid on or before Friday, September 8, 2023.

The company has delivered returns of 22 per cent over the past year and great returns of 110 per cent over the past 3 years. Additionally, the company has a ROCE of 17.4 per cent and a ROE of 16.6 per cent.

On Monday, shares of the company surged by 0.56 per cent to trade at Rs 1,041.25.

Investors should keep a close eye on this dividend paying stock.

Previous Article This multibagger railways wagon company emerges as the lowest bidder for order worth Rs 808.48 crore from National Highways Authority of India!
Next Article These 3 BSE Small-cap stocks jumped by more than 4 per cent today!
Rate this article:
4.1

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR